M. R. Theoret, Y. M. Ning, J. J. Zhang, R. Justice, P. Keegan and R. Pazdur, “The Risks and Benefits of 5α-Reductase Inhibitors for Prostate-Cancer Prevention,” The New England Journal of Medicine, Vol. 365, No. 2, 2011, pp. 97- 99. doi:10.1056/NEJMp1106783

has been cited by the following article:

• TITLE: Role of Prostate Specific Antigen (PSA) in Pathogenesis of Prostate Cancer

  AUTHORS: Saleh Altuwaijri

  KEYWORDS: Prostate Cancer; Prostate Specific Antigen; PSA; Androgen Receptor

  JOURNAL NAME: Journal of Cancer Therapy, Vol.3 No.4, August 9, 2012

  ABSTRACT: Prostate cancer (PCa) is most common diagnosed cancer in men and it is second most common cause of male cancer death. Many factors have been implicated in the pathogenesis of PCa. Although many papers have discussed the prostate specific antigen (PSA) as biomarker of PCa, very few have addressed its rule in the carcinogenesis, metastasis and invasion of PCa. In this article we will review the pathological role of PSA, as a potential target in the therapeutics of PCa.